Voyager Therapeutics, Inc. (NASDAQ:VYGR) shares shot up 4.3% on Thursday . The stock traded as high as $13.71 and last traded at $14.21. 429,646 shares traded hands during mid-day trading, an increase of 156% from the average session volume of 167,827 shares. The stock had previously closed at $13.63.

Several brokerages recently weighed in on VYGR. Evercore ISI began coverage on shares of Voyager Therapeutics in a report on Wednesday, August 16th. They issued an “outperform” rating and a $12.00 target price for the company. Zacks Investment Research cut shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. ValuEngine cut shares of Voyager Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, July 28th. BidaskClub upgraded shares of Voyager Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, July 13th. Finally, Cowen and Company reiterated a “buy” rating on shares of Voyager Therapeutics in a research note on Tuesday, August 8th. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $23.43.

The company’s market cap is $392.51 million. The company has a 50 day moving average of $9.43 and a 200 day moving average of $10.31.

Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Tuesday, August 8th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by $0.11. Voyager Therapeutics had a negative net margin of 712.22% and a negative return on equity of 46.15%. The company had revenue of $1.18 million during the quarter, compared to analyst estimates of $3.27 million. On average, equities analysts forecast that Voyager Therapeutics, Inc. will post ($2.84) earnings per share for the current year.

In other news, insider Bernard Ravina sold 5,490 shares of Voyager Therapeutics stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $10.00, for a total value of $54,900.00. Following the sale, the insider now owns 17,157 shares in the company, valued at $171,570. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 6.00% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in VYGR. Teachers Advisors LLC grew its position in shares of Voyager Therapeutics by 9.8% in the fourth quarter. Teachers Advisors LLC now owns 20,604 shares of the company’s stock valued at $262,000 after purchasing an additional 1,847 shares during the period. Wells Fargo & Company MN grew its position in shares of Voyager Therapeutics by 114.4% in the first quarter. Wells Fargo & Company MN now owns 83,577 shares of the company’s stock valued at $1,107,000 after purchasing an additional 44,599 shares during the period. Bank of New York Mellon Corp grew its position in shares of Voyager Therapeutics by 15.6% in the first quarter. Bank of New York Mellon Corp now owns 44,018 shares of the company’s stock valued at $582,000 after purchasing an additional 5,952 shares during the period. Wellington Management Group LLP grew its position in shares of Voyager Therapeutics by 17.4% in the first quarter. Wellington Management Group LLP now owns 131,312 shares of the company’s stock valued at $1,739,000 after purchasing an additional 19,450 shares during the period. Finally, Schwab Charles Investment Management Inc. grew its position in shares of Voyager Therapeutics by 3.7% in the first quarter. Schwab Charles Investment Management Inc. now owns 28,921 shares of the company’s stock valued at $383,000 after purchasing an additional 1,026 shares during the period. Institutional investors and hedge funds own 40.70% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Voyager Therapeutics, Inc. (VYGR) Shares Up 4.3%” was originally published by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/09/09/voyager-therapeutics-inc-vygr-shares-up-4-3-2.html.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.